Warsaw, Poland, 13 June 2019 - Generic, biosimilar and value added medicine manufacturers deliver increased access to medicines worldwide. This access could be threatened by shortsighted cost-containment policies that make manufacturing and supply unsustainable. Focused pharmaceutical policies based on healthy competition, regulatory convergence, biosimilar medicines uptake and continuous innovation will deliver efficiency for healthcare, improved access to medicines and opportunities for manufacturers to invest for the future.
Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Health Canada made the decision following a domestic consultation process with stakeholders.
February 22, 2019 – Toronto – The following is a statement by Jim Keon, Chair of the International Generic and Biosimilars medicines Association (IGBA), on the passing of Dilip Shah, Secretary-General of the Indian Pharmaceutical Association (IPA).
- Suzette Kox nominated as Secretary General of the International Generic and Biosimilar medicines Association
- IGBA Reflection Paper on waiving bridging studies for biosimilar medicines applications
- IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures
- IGBA submission to HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49]